LRP5 is a gene whose protein helps decide how much new bone your body builds.1Japanese Dental Science Review. Roles of Wnt signaling in bone formation and resorption Changes that turn it down cause low bone density and fractures, sometimes with eye problems, while a few specific changes that block its natural brakes produce unusually dense, strong bones.2PubMed. The binding between sclerostin and LRP5 is altered by DKK1 and by high-bone mass LRP5 mutations That two-way effect is why the same gene name appears on reports for childhood osteoporosis and for families whose bones rarely break. The brake system LRP5 works against is now the target of an approved osteoporosis drug.3PubMed Central. Sclerostin inhibition: a novel therapeutic approach in the treatment of osteoporosis
What the LRP5 Gene Does in Your Bones
LRP5 sits on the surface of bone cells and acts as a receiving partner for Wnt signals, chemical messages that tell cells to build bone. When a Wnt message arrives, LRP5 works with a partner receptor to switch on the cell’s bone-building machinery.4Journal of Bone and Mineral Research. LRP5 and Wnt Signaling: A Union Made for Bone The strength of that signal helps set your bone mineral density (BMD), the number a bone scan reports. The first clue to all this came when people with broken LRP5 genes were found to have low bone mass.5Japanese Dental Science Review. Roles of Wnt signaling in bone formation and resorption
Bone cells also release brake proteins, mainly sclerostin and one called DKK1, that latch onto LRP5 and block the signal.6PubMed. The binding between sclerostin and LRP5 is altered by DKK1 and by high-bone mass LRP5 mutations Your bone density reflects the balance of signal and brakes over years, and a gene change can either weaken the receptor or make the brakes slip off.
Bone needs this constant tuning because it is living tissue, broken down and rebuilt throughout life. The work is done by teams: cells that dissolve a small patch of old bone clear a pit, then cells that build bone fill it with new material. Because this happens in countless tiny patches all over the skeleton, total bone depends on whether the filling keeps pace with the clearing. If building lags removal, density falls and fracture risk rises.
The bone-building signal also helps bone cells hold back the cells that dissolve bone.7PubMed. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation So LRP5 affects both how much bone is laid down and how much is removed. A weak signal leaves pits underfilled, and a strong one overfills them.
A bone density scan compares your bone to a reference group, so a low score measures the outcome and does not diagnose its cause. LRP5 is only one of many influences on that score.
Why One Gene Can Cause Weak or Very Dense Bones
The direction depends on what the change does to the protein. Changes that switch LRP5 off cause low bone mass, while changes that make it overactive cause high bone mass.8PubMed. The binding between sclerostin and LRP5 is altered by DKK1 and by high-bone mass LRP5 mutations Depending on the change, LRP5 problems can affect bone, the blood vessels of the retina, or both.9Gene Reports. A novel splice-site mutation in the LRP5 gene causing Familial Exudative Vitreoretinopathy The dense-bone changes cluster in one front part of the protein, where the brakes attach.10PubMed Central. Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density11PubMed. Wnt antagonists bind through a short peptide to the first β-propeller domain of LRP5/6
On a report, “loss-of-function” means the protein works less or not at all, which points toward weaker bone. “Gain-of-function” means the signal runs stronger than normal, which points toward denser bone. The specific variant name, not just the gene, decides the direction. It is usually written as a letter, a number, and another letter (like G171V), which names the exact swap in the protein. Two different changes in the same gene can have opposite effects, so a report that merely mentions LRP5 does not say whether bone will be weaker or denser.
Lab labels such as pathogenic, likely pathogenic, or uncertain significance describe how confident the lab is that a change causes disease, not how severe it is. Many reported variants are of uncertain significance. For those, the honest answer is that the effect is not yet known, and a clinical geneticist can weigh the variant against your scan results and family history.
Loss-of-Function Changes and Fragile Bones
When both copies of LRP5 are broken, a child develops osteoporosis-pseudoglioma syndrome, or OPPG.12PubMed Central. Clinical and molecular findings in osteoporosis-pseudoglioma syndrome It means severe osteoporosis beginning early in life together with blindness.13PubMed Central. Novel mutations affecting LRP5 splicing in patients with osteoporosis-pseudoglioma syndrome (OPPG) The eyes are involved because LRP5 is also needed to grow normal blood vessels in the eye.14PubMed Central. Mutations in LRP5 or FZD4 underlie the common familial exudative vitreoretinopathy locus on chromosome 11q Some LRP5 changes cause a retinal blood vessel disease without the bone problem.15PubMed Central. Mutations in LRP5 or FZD4 underlie the common familial exudative vitreoretinopathy locus on chromosome 11q
In a family, the parents each usually carry one changed copy without severe disease. Each child of two carrier parents has a 1 in 4 chance of OPPG. Vision problems often appear in infancy before fractures, so a baby may first be seen by an eye specialist for poor vision or an abnormal-looking retina. Bone symptoms come later: fractures from minor falls or very little force, bone pain, or deformity. An X-ray or scan shows thin, low-density bones. Genetic testing of LRP5 can confirm the diagnosis and separate OPPG from other causes of childhood fractures. Finding two changed copies in a child means each parent is expected to carry one, which prompts testing and counseling for the wider family.
One changed copy can still cause osteoporosis in children and adults.16PubMed. Heterozygous mutations in the LDL receptor-related protein 5 (LRP5) gene are associated with primary osteoporosis in children In one family, the father, brother, and other relatives carrying the same change also had significant osteoporosis.17PubMed. Heterozygous mutations in the LDL receptor-related protein 5 (LRP5) gene are associated with primary osteoporosis in children These changes reduce the bone-building signal.18PubMed Central. Mutations in LRP5 cause primary osteoporosis without features of OI by reducing Wnt signaling activity Each child has a 50% chance of inheriting one copy, and relatives may benefit from a bone density scan. Unexplained osteoporosis in a young person or in several relatives can point toward LRP5.
A weakened receptor also blunts bone’s response to use. In mice without working Lrp5, bone barely grew in response to loading, with the response reduced by 88 to 99%.19PubMed. The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment Removing Lrp5 from bone’s sensing cells made bones smaller and much less stiff in mice.20PubMed Central. Inactivation of Lrp5 in Osteocytes Reduces Young’s Modulus and Responsiveness to the Mechanical Loading Part of the fragility may therefore be that bones don’t strengthen properly with everyday movement.
High Bone Mass Changes and Unusually Strong Bones
A family with very high bone density was traced to one LRP5 change, known as G171V.21PubMed. High bone density due to a mutation in LDL-receptor-related protein 5 Several other changes in the same region cause dense bones mainly in the skull and the walls of the long bones.22PubMed Central. Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density These altered receptors bind sclerostin and DKK1 poorly, so the brakes don’t work.23PubMed. LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST One copy is enough, so each child of an affected parent has a 50% chance of inheriting it.24PubMed. The binding between sclerostin and LRP5 is altered by DKK1 and by high-bone mass LRP5 mutations
The bones really are stronger. In mice with the G171V change, bones in the thigh, shin, and spine were stronger and stiffer.25PubMed. Bone biomechanical properties in LRP5 mutant mice They built extra bone in response to normal loads,26PubMed Central. Mechanotransduction in bone tissue: The A214V and G171V mutations in Lrp5 enhance load-induced osteogenesis in a surface-selective manner and the dense bone kept accumulating with age.27PubMed Central. Gain‐of‐Function Lrp5 Mutation Improves Bone Mass and Strength and Delays Hyperglycemia in a Mouse Model of Insulin‐Deficient Diabetes
Thick bone can cause problems in the head, though. Common features include a prominent forehead, a flat nasal bridge, and bony lumps on the roof of the mouth or jaw.28PubMed Central. LRP5 high bone mass Worth-type autosomal dominant endosteal hyperostosis case report and historical review of the literature A lump on the roof of the mouth is reported in about 41% of people with this condition.29PubMed Central. LRP5 high bone mass Worth-type autosomal dominant endosteal hyperostosis case report and historical review of the literature About 19% develop nerve problems or other neurological complications, likely from thickened skull bone.30PubMed Central. LRP5 high bone mass Worth-type autosomal dominant endosteal hyperostosis case report and historical review of the literature Overgrowth in the wrong places can crowd the openings where nerves and vessels pass through the skull. Headache and facial paralysis have been reported.31PubMed Central. Novel mutation in LRP5 gene cause rare osteosclerosis: cases studies and literature review Many people have few or no symptoms.
People often find out by chance, when a bone scan shows very high density. A dentist may notice lumps on the jaw or palate, and some learn after surviving an injury without a fracture. New hearing loss, facial weakness, or a persistent headache deserves evaluation. Dental work can be harder with dense jawbone, but most features are cosmetic or mild.
Treatment When You Have a Weak-Bone LRP5 Variant
Understanding sclerostin’s brake led to antibodies that block it, including romosozumab.32PubMed Central. Sclerostin inhibition: a novel therapeutic approach in the treatment of osteoporosis In people with one changed copy of LRP5, LRP6, or WNT1, romosozumab raised spine density by about 16%.33PubMed Central. Romosozumab is effective in patients with variants in LRP5, LRP6, or WNT1 Standard drugs that slow bone loss raised it by only about 4% in the same group.34PubMed Central. Romosozumab is effective in patients with variants in LRP5, LRP6, or WNT1 A sclerostin-blocking antibody also strengthened bones in a mouse model of brittle bone disease.35PubMed Central. Targeting the LRP5 pathway improves bone properties in a mouse model of Osteogenesis Imperfecta
If the problem is a weak signal from a damaged LRP5, blocking sclerostin can turn up signaling through whatever receptor function remains. That fits the finding in people with one changed copy, where some working LRP5 is left. It is less certain for someone with two broken copies, because the receptor is largely missing and the evidence there is limited. The result also came from a small group, so it is promising rather than settled for every variant.
Romosozumab is given as monthly injections for 12 months, usually followed by a drug that slows bone loss to keep the gains. It carries a warning about heart attack and stroke risk. It is approved for adults with high fracture risk, not routinely for children.
Other options exist. In mice lacking Lrp5, parathyroid hormone treatment still built bone.36PubMed. The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment Gene-based or gut-hormone approaches remain at the lab stage.37PubMed Central. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum: an entero-bone endocrine axis
A bone specialist can tell you whether a bone-building drug suits your variant. Useful questions: Does my specific variant reduce or increase LRP5 activity? Is a bone-building drug better than a bone-loss-slowing drug for me? Should my relatives have bone scans or genetic testing?
Exercise, Everyday Habits, and LRP5
Loading builds bone through LRP5, and that response falls sharply when LRP5 is missing in mice.38PubMed. The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment Weight-bearing exercise, calcium, vitamin D, and fall prevention remain standard bone care, and they work best paired with medical treatment when it’s needed. Exercise is still worth doing even if your bones respond less, because it builds muscle strength and balance, which lowers the chance of falling.
With fragile bones, walking and balance training reduce fall risk. If you have already had fractures, avoid high-impact twisting or heavy spinal flexion. A physical therapist can tailor a plan, and home hazards like loose rugs are worth fixing.
For children with OPPG, gentle activity like swimming builds muscle with low fracture risk. Vision loss adds fall risk that needs planning, and school staff should know about the fracture risk.
Common LRP5 Variants and Your Fracture Risk
Common LRP5 variations have been linked to fracture risk in older white men.39PubMed. Common genetic variation of the low-density lipoprotein receptor-related protein 5 and 6 genes determines fracture risk in elderly white men Rarer variants in LRP5 and related genes raised the risk of major osteoporotic fracture by about a third per step down in bone quality score.40Journal of Bone and Mineral Research. Identifying Rare Genetic Determinants for Improved Polygenic Risk Prediction of Bone Mineral Density and Fracture Risk Adding them barely improved predictions of who would break a bone, though.41Journal of Bone and Mineral Research. Identifying Rare Genetic Determinants for Improved Polygenic Risk Prediction of Bone Mineral Density and Fracture Risk Age, sex, smoking, steroid use, and prior fractures matter more for most people.
A consumer DNA result for LRP5 is not a substitute for a bone density scan, which measures what genes only hint at. An unexpected result can be confirmed through clinical genetic testing. Testing is worth considering for osteoporosis in a child or young adult without obvious cause, for several relatives with early fractures or very dense bones, or for eye blood vessel disease together with low bone density.